NorInvent is closing its new share issue, which aimed to obtain additional shareholders, of approximately SEK 6.4 million. The company will now begin the listing process for AktieTorget. More details will be presented in March.
About the company:
NorInvent AB is a development company within the Life Science sector that develops drug delivery platforms. The technology, XtriG, is based on carbohydrates bound to a membrane and placed under the lip for rapid absorption. The company's technology is patented and preliminarily comprises an excipient for pharmaceutical substances.
NorInvent is a SmiLe company.
For additional information, please contact:
Ebba Fåhraeus, CEO at SmiLe Incubator
Mobile: +46 734000433
Or visit our mediaroom
SmiLe is a business incubator based in Medicon Village in Lund. SmiLe helps entrepreneurs and startup companies to develop and commercialize new ideas. Our main task is to help the management teams of these companies to navigate the complexities of business development, financing, recruitment and risk management. There are currently around 20 companies in SmiLe, which together have attracted more than SEK 1 000 million in venture capital to date since 2014. Approximately 100 people, representing 20 nationalities, and almost 50 percent of whom are women, work at SmiLe incubator. SmiLe is a community consisting of experts, business advisors, incubator companies as well as alumni companies, which when combined provide a unique opportunity for Life Science Industry startups to benefit from their extensive collective experience. The opportunity also includes an infrastructure that is unique of its kind in Sweden, with well-equipped laboratories and advanced instrumentation. SmiLe has its major financing from Lunds university, Lund Municipality, Region Skåne och Medicon Village.